Zachary S Wallace

Modeling suggests SARS-CoV-2 rebound after nirmatrelvir-ritonavir treatment is driven by target cell preservation coupled with incomplete viral clearance

M. Siedner, T. Vyas, J. Vyas, 2024, bioRxiv.